terça-feira, 6 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 27, 2026

XRP Price: Why Is XRP Not Going Up? The 3 Things Holding XRP Back

View original at finance.yahoo.com
XRP Price: Why Is XRP Not Going Up? The 3 Things Holding XRP Back Quick Read XRP tracks Bitcoin with a 0.80 correlation, so with BTC stuck between $65,000 and $75,000 and dominance above 58%, XRP can’t rally regardless of its own fundamentals…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Futures markets aren't pricing in a Fed rate cut before December at the earliest

    60% confidence
  • Bitcoin ETFs have bled over $3.8 billion in outflows since January

    60% confidence
  • 84% of XRP ETF money is coming from retail investors

    60% confidence
  • XRP whales have cashed out an estimated $6 billion since the $3.65 peak

    60% confidence
  • XRP tracks Bitcoin roughly 80% of the time with a correlation of 0.80

    60% confidence
  • XRP swings about 1.8 times more than Bitcoin in either direction

    60% confidence
  • 60% of XRP's circulating supply is held at a loss

    60% confidence
  • XRP ETF weekly inflows collapsed from $200 million at launch to under $2 million

    60% confidence

Data points we hold from this source

XRP · return from peak-60 percent
XRP · supply held at loss60 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com